ArticleMolecular psychiatry2026
Large-scale proteomic analyses before depression diagnosis reveal novel pathophysiological insights.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe early pathophysiology of depression is poorly understood. We elucidated the decadal temporal evolution of plasma proteomic alterations before depression diagnosis and evaluated their associations with comorbid conditions and neuroanatomical changes.
methodsThis study analyzed 31,114 depression-free participants and identified 1555 incident depression cases after a median follow-up of 7.8 years. Cox regression was used to identify depression-associated proteins, adjusting for sociodemographic, lifestyle, and genetic factors. Subsequent analyses of depression-related proteins included exome-wide association analysis (EWAS), temporal change modeling of pre-diagnostic protein dynamics via LOESS regression, association analyses with eight comorbid conditions and 58 regional brain volumes, and LightGBM-based predictive modeling.
resultWe found 64 depression-related proteins, with PIGR, HAVCR2, and IL4R validated in EWAS. For example, PIGR exhibited risk effects for depression (HR = 1.26, 95%CI: 1.13-1.40) and comorbid conditions, particularly diabetes (HR = 2.34, 95%CI: 2.12-2.58). Temporal profiling identified three protein clusters: one (cell-matrix adhesion) characterized by initial stability and subsequent decline, another (including PIGR and HAVCR2) characterized by MAPK cascade activation, and the third characterized by increased apoptosis and immune response. Neuroimaging correlations confirmed that elevated PIGR levels were associated with reduced volume in the bilateral ventral diencephalon (β = -0.062--0.061). A predictive model combined proteins and clinical features, achieving superior accuracy in depression prediction after 15 years (area under the curve = 0.74). Our findings reveal early peripheral pathophysiological changes in depression, suggesting a progression that may involve early apoptotic processes, an intermediate inflammatory phase, and later proteolytic dysregulation.
conclusionThese insights hold significant potential for developing early biomarkers and precision therapies.
Indexed as
Identifiers
41862570What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.